The difference between Mounjaro and retatrutide — and why it matters right now

You've read the retatrutide headlines, here's what they mean in practice

The scenario is familiar. A trial result lands in the news, social media fills with comparison posts, and patients reasonably ask whether the new thing is better than what they're already taking. Retatrutide generated exactly that wave of attention after phase 2 trial data were published in The Lancet in 2023, reporting average weight reductions of around 24% over 48 weeks at the highest dose tested in adults with obesity, figures that attracted genuine scientific interest.

The critical context is that a phase 2 trial is a relatively small, early-stage study designed primarily to assess dosing and tolerability, not to confirm efficacy at scale. Phase 3 trials, which involve thousands of participants across diverse populations and are the basis for regulatory decisions, were still under way at the time this page was written. The full retatrutide vs Mounjaro comparison covers the trial pipeline in more detail if you want the research timeline. For now, the short version: retatrutide is not licensed, not approved, and not available for prescription anywhere, including the UK.

Mounjaro, by contrast, has completed a substantial clinical programme. SURMOUNT-1 randomised 2,539 adults and reported average weight loss of around 20–21% at the 15mg dose over 72 weeks, as published in the New England Journal of Medicine. That evidence base is what underpins its UK licence and NICE recommendation.

What makes retatrutide different from tirzepatide, the mechanism

To understand the difference between retatrutide and tirzepatide (the molecule in Mounjaro), it helps to look at what each targets. The difference between Mounjaro and tirzepatide is, of course, nothing, they are the same molecule; Mounjaro is simply the brand name. Both refer to a dual agonist that activates GIP and GLP-1 receptors.

Retatrutide adds a third target: the glucagon receptor. Glucagon normally raises blood glucose and also plays a role in fat metabolism. The hypothesis behind triple agonism is that adding glucagon receptor activation on top of GIP and GLP-1 stimulation could drive additional energy expenditure and fat breakdown, potentially producing greater weight loss than a dual agonist alone. If you want a detailed breakdown, our page on the difference between reta and Mounjaro sets out how the two medicines compare across mechanism, trial data, and availability. The phase 2 data are consistent with that hypothesis, which is why researchers and clinicians are watching the phase 3 results closely.

Whether the extra mechanism translates into meaningfully better outcomes across a broad population, and with an acceptable side-effect profile, is precisely what large-scale trials exist to determine. The deeper look at how GLP-1 and dual agonism differ on this site explains the receptor biology in more accessible terms if that part is useful.

A quick check worth doing: if you encounter a website claiming to sell or prescribe retatrutide in the UK, search its name on the GPhC pharmacy register. An unlicensed medicine cannot legally be prescribed or dispensed through a registered UK pharmacy, absence from the register is a red flag in itself.

Side-effect profile: what's known and what isn't yet

For Mounjaro, the safety picture is well-established. The most commonly reported effects are gastrointestinal: nausea is the one most patients mention first, typically peaking after starting or after a dose increase and settling within one to two weeks for most people. Constipation, loose stools, indigestion and reduced appetite sit alongside it. Injection-site reactions, mild fatigue and occasional headaches round out the common picture. The NHS tirzepatide page lists these in full alongside the rarer events worth knowing about.

For retatrutide, the phase 2 data reported a broadly similar GI-led profile, with nausea, vomiting and diarrhoea the most frequent findings. Glucagon receptor agonism does raise some theoretical questions about longer-term metabolic effects that phase 3 data will need to address. That is not a reason to dismiss retatrutide's potential; it is a reason why the regulatory process exists and why it takes time.

The honest answer is that we simply do not yet have the depth of safety data for retatrutide that exists for tirzepatide. Prescribing a medicine without that data, outside a clinical trial, would not meet UK regulatory standards, and rightly so.

What this means if you're trying to decide what to do now

If retatrutide is approved in future, it will require a clinical assessment and a valid prescription, just as Mounjaro does. The comparison table below captures where each medicine currently stands.

People sometimes ask about the difference between mounjaro and tirzepatide in this context, wondering whether they've missed a separate product. They haven't. Mounjaro is tirzepatide. The page on what separates Mounjaro from tirzepatide covers the brand-versus-molecule question directly.

For context on how Mounjaro sits alongside other licensed options already available in the UK, the comparison of liraglutide and tirzepatide covers an older GLP-1 against the current dual agonist. And for an overview of Mounjaro itself, the Mounjaro treatment page sets out how it works, who it's licensed for, and how the titration schedule is structured.

Which medicine suits you is a clinical decision our prescribers make with you, based on your health history, current medicines, and treatment goals. Speak to our prescribers through a free consultation and get a same-day clinical review from a real clinician, not a queue for an algorithm.